Top

Published in:

01-02-2020 | Positron Emission Tomography | Letter to the Editor

Letter to the Editor re: “Semiquantitative Parameters in PSMA-Targeted PET Imaging with [¹⁸F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake”

Authors: Rudolf A. Werner, Kenneth J. Pienta, Martin G. Pomper, Michael A. Gorin, Steven P. Rowe, Martin A. Lodge, Ralph A. Bundschuh

Published in: Molecular Imaging and Biology | Issue 1/2020

Excerpt

We greatly appreciate the insightful comments of Dr. Cysouw and colleagues in their letter to the editor regarding our recent article [1], and generally agree with the points raised by the authors [2]. We appreciate the contributions that the same group has made in evaluating kinetic parameters in patients imaged with a prostate-specific membrane antigen (PSMA)-targeted positron emission tomography agent [3]. Thoughtful discussions regarding the quantitation of new radiotracers, particularly agents as important to the field of nuclear medicine as PSMA-targeted small molecules for positron emission tomography (PET) imaging, such as [¹⁸F]DCFPyL, are vital to eventual widespread adoption and appropriate utilization. …

Werner RA, Bundschuh RA, Bundschuh L et al (2019) Semiquantitative parameters in PSMA-targeted PET imaging with [¹⁸F]DCFPyL: impact of tumor burden on normal organ uptake. Mol Imaging Biol. https://doi.org/10.1007/s11307-019-01375-w

Cysouw M, Jansen BHE, Yaqub MM et al (2019) Letter to the Editor Re: semiquantitative parameters in PSMA-targeted PET Imaging with [18F]DCFPyL: impact of tumor burden on normal organ uptake. Mol Imaging Biol. https://doi.org/10.1007/s11307-019-01438-y

Jansen BHE, Yaqub M, Voortman J et al (2019) Simplified methods for quantitation of ¹⁸F-DCFPyL uptake in patients with prostate cancer. J Nucl Med. https://doi.org/10.2967/jnumed.119.227520 CrossRef

Rowe SP, Campbell SP, Mana-Ay M et al (2019) Prospective evaluation of PSMA-targeted ¹⁸F-DCFPyL in men with biochemical failure after radical prostatectomy for prostate cancer. J Nucl Med. https://doi.org/10.2967/jnumed.119.226514 CrossRef

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA (2019) Assessment of ⁶⁸Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol 5:856–863CrossRef

Radwan N, Phillips R, Ross A et al (2017) A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate cancer (ORIOLE). BMC Cancer 17:453CrossRef

Gaertner FC, Halabi K, Ahmadzadehfar H et al (2017) Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget 8:55094–55103CrossRef

Sahakyan K, Li X, Lodge MA et al (2019) Semiquantitative parameters in PSMA-targeted PET imaging with [¹⁸F]DCFPyL: intrapatient and interpatient variability of normal organ uptake. Mol Imaging Biol. https://doi.org/10.1007/s11307-019-01376-9

Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, Baum RP, Kulkarni HR, Schmidt M, Drzezga A, Bartenstein P, Pfestroff A, Luster M, Lützen U, Marx M, Prasad V, Brenner W, Heinzel A, Mottaghy FM, Ruf J, Meyer PT, Heuschkel M, Eveslage M, Bögemann M, Fendler WP, Krause BJ (2017) German multicenter study investigating ¹⁷⁷Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med 58:85–90CrossRef

10.

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S (2018) [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 19:825–833CrossRef

11.

Sethekge M, Bruchertseifer F, Knoesen O et al (2019) ²²⁵Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 46:129–138CrossRef

12.

Wondergem M, van der Zant FM, Vlottes PW, Knol RJJ (2018) Effects of fasting on ¹⁸F-DCFPyL uptake in prostate cancer lesions and tissues with known high physiologic uptake. J Nucl Med 59:1081–1084CrossRef

13.

Kulkarni HR, Singh A, Langbein T et al (2018) Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. Br J Radiol 91:20180308CrossRef

14.

Ilan E, Velikyan I, Sandstrom M, Sundin A, Lubberink M (2019) Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE. J Nucl Med. https://doi.org/10.2967/jnumed.119.228072 CrossRef

15.

Kotasidis FA, Tsoumpas C, Rahmim A (2014) Advanced kinetic modelling strategies: towards adoption in clinical PET imaging. Clin Transl Imaging 2:219–237CrossRef

16.

Cheebsumon P, Velasquez LM, Hoekstra CJ, Hayes W, Kloet RW, Hoetjes NJ, Smit EF, Hoekstra OS, Lammertsma AA, Boellaard R (2011) Measuring response to therapy using FDG PET: semi-quantitative and full kinetic analysis. Eur J Nucl Med Mol Imaging 38:832–842CrossRef

Title: Letter to the Editor re: “Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake”
Authors: Rudolf A. Werner
Kenneth J. Pienta
Martin G. Pomper
Michael A. Gorin
Steven P. Rowe
Martin A. Lodge
Ralph A. Bundschuh
Publication date: 01-02-2020
Publisher: Springer International Publishing
Keyword: Positron Emission Tomography
Published in: Molecular Imaging and Biology / Issue 1/2020
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-019-01452-0

At a glance: The STEP trials

Springer Medicine

Letter to the Editor re: “Semiquantitative Parameters in PSMA-Targeted PET Imaging with [¹⁸F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake”

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

In Response to Letter from Fregonara et al. 2019

Comparison of [18F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study

Renal Damages in Deoxycorticosterone Acetate–Salt Hypertensive Rats: Assessment with Diffusion Tensor Imaging and T2-mapping

Research Progress of [68Ga]Citrate PET’s Utility in Infection and Inflammation Imaging: a Review

Correction to: The 2019 World Molecular Imaging Congress (WMIC) and Molecular Imaging and Biology (MIB) Awards

PET/CT-Based Response Evaluation in Cancer—a Systematic Review of Design Issues